Results 151 to 160 of about 62,474 (297)

Off-Label Use of Bevacizumab in Patients Diagnosed with Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis

Pharmaceuticals
Background: Age-related macular degeneration (AMD) is the leading cause of vision loss in elderly people. Current pharmacological treatment in vascular AMD includes anti-VEGF agents, such as ranibizumab and aflibercept. Additionally, the off-label use of
João Estarreja, Priscila Mendes, Carina Silva, Pedro Camacho, Vanessa Mateus   +4 more
doaj   +1 more source

Imaging polarimetry in patients with neovascular age-related macular degeneration [PDF]

, 2007
Ann E. Elsner, Anke Weber, Michael C. Cheney, Dean A. VanNasdale, Masahiro Miura   +4 more
openalex   +1 more source

Deep Learning for Retinal Degeneration Assessment: A Comprehensive Analysis of the MARIO AMD Progression Challenge [PDF]

arXiv
The MARIO challenge, held at MICCAI 2024, focused on advancing the automated detection and monitoring of age-related macular degeneration (AMD) through the analysis of optical coherence tomography (OCT) images. Designed to evaluate algorithmic performance in detecting neovascular activity changes within AMD, the challenge incorporated unique multi ...
arxiv  

Relationships between Patient-Reported Outcome Measures and Clinical Measures in Naïve Neovascular Age-Related Macular Degeneration Patients Treated with Intravitreal Ranibizumab

Pharmaceuticals
Our objective was to evaluate changes in patient-reported outcome measures using the NEI-VFQ 25 questionnaire during a treat and extend regimen in naive neovascular Age-Related Macular Degeneration patients, and its correlation with anatomical and ...
Pablo Almuiña-Varela, Laura García-Quintanilla, María José Rodríguez-Cid, María Gil-Martínez, Maximino J. Abraldes, Francisco Gómez-Ulla, Ana Estany-Gestal, Jorge Miguel Alcántara-Espinosa, Maribel Fernández-Rodríguez, Anxo Fernández-Ferreiro   +9 more
doaj   +1 more source

Retinal pigment epithelial tear following intravitreal bevacizumab for choroidal neovascular membrane due to age-related macular degeneration [PDF]

, 2007
Shabeeba Hannan, Krishnappa C. Madhusudhana, Andrew Lotery, Richard Newsom   +3 more
openalex   +1 more source

Review of Guideline Recommendations for Optimal Anti-VEGF Therapy in Age-Related Macular Degeneration

Life
Neovascular age-related macular degeneration is a progressive, blinding macular disease that has become a burden both in healthcare systems and the global economy. The vascular endothelial growth factor (VEGF) is the main agent involved in the pathogenic
Andreea Dana Moraru, Ciprian Danielescu, Raluca Eugenia Iorga, Radu Lucian Moraru, Mihail Zemba, Daniel Constantin Branisteanu   +5 more
doaj   +1 more source

Full macular translocation following photodynamic therapy in neovascular age-related macular degeneration [PDF]

, 2007
Daniela Suesskind, M. Voelker, K. U. Bartz-Schmidt, Faik Gelişken   +3 more
openalex   +1 more source

Current status of anti-vascular endothelial growth factor therapy in Europe [PDF]

, 2018
Vascular endothelial growth factor (VEGF) is an important modulator of angiogenesis, and has been implicated in the pathology of a number of conditions, including age-related macular degeneration (AMD), diabetic retinopathy, and cancer.
Wolf, Sebastian
core  

Characterizing the circularly-oriented macular pigment using spatiotemporal sensitivity to structured light entoptic phenomena [PDF]

arXiv
The macular pigment (MP) in the radially-oriented Henle fibers that surround the foveola enables the ability to perceive the orientation of polarized blue light through an entoptic phenomena known as the Haidinger's brush. The MP has been linked to eye diseases and central field dysfunctions, most notably age-related macular degeneration (AMD), a ...
arxiv  

New treatments for neovascular age‐related macular degeneration: when should we use them? [PDF]

, 2007
Anders Kvanta
openalex   +1 more source